Sandoz Group AG (SDZ.SW)
Sandoz Group AG (SDZ.SW) Stock Price, Analysis & Data
Keine Daten verfügbar
| Geld | 73.76 |
| Marktkapitalisierung | 31.92 Mrd |
| Umsatz (TTM) | 11.68 Mrd |
| Nettogewinn (TTM) | 646 Mio |
| Beta | 0.49 |
| EPS (ttm) | 1.2 |
| KGV (TTM) | 62.51 |
| Forward-KGV | 19.96 |
| KBV (TTM) | 4.20 |
| KUV (TTM) | 2.73 |
| Earnings Date | Feb 17, 2027 |
| Brief | 73.8 |
| Volumen | 194,412 |
| Ø Vol. (20D) | 746,109 |
| Eröffnung | 73.12 |
| Vortagesschluss | 73.40 |
| Tagesspanne | 73.12 - 74.26 |
| 52-Wk Range | 43.86 - 75.90 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | $0.8 (1.09%) |
| Ex-Dividenden-Datum | 13. Apr. 2026 |
Über SDZ.SW
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage...
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von Sandoz 11.16 Mrd, ein Anstieg von 7.44% im Vergleich zum Vorjahr (10.38 Mrd). Der Gewinn lag bei 914 Mio, ein Anstieg von undefined %.
Finanzzahlen in CHF FinanzberichteAnalysten erwarten einen Umsatz von ... Upgrade
vor 1 Woche · The Wall Street Journal
Sandoz in Talks With U.S. Government About Potential Investment, CEO SaysSandoz Group is in talks with the U.S. government about manufacturing investments in the country and doesn’t see President Trump’s planned tariffs on generic medicines as a major threat, the drugmaker...